tiprankstipranks
Trending News
More News >
Elementis PLC (GB:ELM)
LSE:ELM

Elementis (ELM) AI Stock Analysis

Compare
28 Followers

Top Page

GB:ELM

Elementis

(LSE:ELM)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 5.2)
Rating:58Neutral
Price Target:
158.00 p
▲(3.67% Upside)
Action:ReiteratedDate:03/07/26
The score is mainly supported by improving financial resilience (much lower debt and continued positive free cash flow) and a constructive earnings-call outlook with margin/EPS progress and clear medium-term targets. These positives are tempered by weak technical momentum (below major moving averages with negative MACD) and valuation risk tied to ongoing net losses (negative P/E), alongside recent revenue softness.
Positive Factors
Leverage materially reduced; stronger balance sheet
Material debt reduction and a sizable equity base lower refinancing and solvency risk, giving management durable financial flexibility. This supports bolt‑ons, targeted capex and dividends while insulating the business from cyclical downturns and reducing probability of distress over the medium term.
Sustained margin expansion and operating profit growth
Consistent operating margin improvement driven by cost programs and pricing demonstrates structural ability to convert sales into profits. Executing self‑help savings and operational fixes suggests margins can be sustained or improved even if top line is soft, underpinning medium‑term cash generation.
Innovation and high‑margin Personal Care growth
Record innovation mix and R&D lift, plus a focused bolt‑on in Personal Care, reinforce a shift toward higher‑margin specialty offerings. Rising innovation sales and targeted M&A increase differentiation, stickier customer relationships and structural margin uplift over the medium term.
Negative Factors
Revenue decline and Coatings weakness
Exposure to cyclical coatings and a recent top‑line decline reduce scale and make margin targets harder to hit consistently. Persistent revenue softness limits operating leverage, raises the bar on innovation/portfolio actions to offset lost volumes, and slows progress on medium‑term growth objectives.
Net losses persisted; negative net margins
Continued below‑the‑line losses indicate structural items, financing or tax impacts that erode shareholder returns despite operating recovery. Negative net margins suppress ROE and make it harder to rebuild retained earnings, limiting capital deployment flexibility over the medium term.
Weaker cash conversion and near‑term leverage pressure
Declining FCF and higher net debt after M&A and shareholder returns tighten financial headroom. Working capital build and capex pressure slow cash conversion, meaningful deleveraging is needed to restore balance‑sheet optionality and fund growth without relying on external financing.

Elementis (ELM) vs. iShares MSCI United Kingdom ETF (EWC)

Elementis Business Overview & Revenue Model

Company DescriptionElementis plc operates as a specialty chemical company in the United Kingdom, North America, rest of Europe, and internationally. It operates through four segments: Personal Care, Coatings, Talc, and Chromium. The Personal Care segment produces and sells rheological modifiers and compounded products for antiperspirants/deodorants, bath and soap, color cosmetics, and hair and skin care products. The Coatings segment produces and sells rheological modifiers and additives for industrial finishes, architectural coatings, construction, adhesives and sealants, inks, colorant dispersions, and specialty applications; and bentonite and hectorite clays, as well as polymer-based additives used in drilling, simulation, and cementing applications. The Talc segment produces and supplies talc for use in plastics, paints and coatings, food and pharmaceuticals, ceramics, polyester putties, paper, and pulp sectors. The Chromium segment produces chromium chemicals, such as chromic oxide, chromic acid, chrome sulfate, sodium dichromate, and sodium sulfate for use in pigments, cosmetics, refractories, chrome metal production, metal and plastic finishing, wood treatment, leather tanning, trivalent metal finishing, coatings, and metal passivation, as well as for making detergents, glasses, papers, and starches. It also offers personal care products, waxes, additives and resins, organoclays, colourants, and other specialty additives. Elementis plc was founded in 1844 and is headquartered in London, the United Kingdom.
How the Company Makes MoneyElementis generates revenue through the sale of specialty chemicals and additives used in a wide range of applications. The company's key revenue streams include the Personal Care sector, where it supplies ingredients for cosmetics and skincare products; the Coatings sector, where it provides solutions for paints and coatings; and the Energy sector, which focuses on drilling and completion fluids for oil and gas extraction. Elementis benefits from long-term contracts with major manufacturers, which provide stable revenue. Additionally, the company's focus on innovation and sustainability drives demand for its products, further enhancing its earnings potential.

Elementis Earnings Call Summary

Earnings Call Date:Mar 05, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call shows a constructive transformation story: management delivered profit growth, margin expansion (+150 bps), strong Personal Care outperformance (revenue +2.4%, profit +16.9%, margin +410 bps), record innovation (16.4%) and continued cost-savings and sustainability progress. Offsetting these positives are modest revenue decline (-1.0% reported / -1.9% CC), Coatings weakness (revenue down ≈3.5% and margin compression), lower free cash flow ($41M vs $51M) and higher leverage (1.3x). Strategic portfolio moves (Alchemy acquisition, Talc sold, pharma disposal) sharpen focus and are accretive over time but change scale. On balance the highlights — margin expansion, EPS growth (+14.2%), successful cost programs, innovation momentum and clear strategic direction — slightly outweigh the near-term operational and macro headwinds.
Q4-2025 Updates
Positive Updates
Adjusted Operating Profit Growth and Margin Expansion
Adjusted operating profit increased 4.6% to $126.7M and group adjusted operating margin improved 150 basis points to 21.2%, demonstrating margin resilience despite a softer demand environment.
Earnings Per Share and Shareholder Returns
Adjusted EPS rose 14.2% to $0.137. The Board recommended a final dividend of $0.03, taking full-year dividend to $0.043 (up 7.5%) and a payout ratio of 31%. The company completed a buyback that cancelled ~4% of issued share capital.
Personal Care Outperformance
Personal Care revenue grew 2.4% to $224.5M; adjusted operating profit rose 16.9% to $72.8M and segment margin expanded 410 basis points to 32.4%, driven by improved volumes, pricing and cost savings.
Portfolio Simplification and Strategic Divestments
Continued transformation into a pure-play specialty chemicals business: Talc previously sold, Chromium exited in 2023, and an agreement reached to sell the pharmaceutical manufacturing business (pharma revenue $35M in prior year). These actions reduce capital intensity and improve pro forma margins.
Bolt-On Acquisition — Alchemy
Acquired Alchemy in November for $20.1M — a bolt-on in Personal Care that is fast-growing, high-margin and strategically synergistic with hectorite and rheology capabilities.
Innovation and R&D Momentum
Innovation sales reached a record 16.4% (doubled over five years); launched 19 new products and sent 1,500+ samples. R&D investment planned to increase from 2% to 3% of revenue, with a medium-term innovation sales target of 20%.
Safety and Sustainability Progress
Achieved first 0 lost time accidents since 2019. Carbon footprint reduced by nearly 80% versus 2019 (divestments and operational changes). Hectorite mine moved to almost entirely renewable energy from a 0% base the prior year.
Cost Savings and Operational Improvements
Delivered $18M of self-help/cost savings in the year; completed the balance of a 2-year $30M program and started an additional $10M program (already delivered $6M, remaining $4M planned by end-2026). Debottlenecking at St. Louis delivered a 20% improvement since H1.
Negative Updates
Group Revenue Decline
Group revenue fell to $597.5M, down 1.0% reported and down 1.9% on a constant currency basis versus prior year, reflecting softer demand in coatings and mix changes.
Coatings Segment Softness and Margin Pressure
Coatings revenue declined from $386.4M to $373.0M (≈ -3.5%). Adjusted operating profit in Coatings decreased and segment margin fell to 18.9% from 20.3%, impacted by absence of prior-year one-off high-margin sales and soft industrial/decorative end markets.
Volume, Mix and One-Off Impacts
Volumes were down $5.6M; mix was adverse by $13.7M (including $3.4M one-off Coatings sales in 2024 not repeated). Pricing offset some inflation (+$7.8M) but did not fully offset mix headwinds.
Lower Free Cash Flow and Working Capital Outflow
Free cash flow declined to $41M from $51M (≈ -19.6%). Adjusted operating cash flow fell to $104.7M from $123.2M (≈ -15.0%) due to higher receivables (less factoring), strategic inventory build and higher CapEx.
Higher Leverage after M&A and Returns
Net debt ended at $185.4M with net debt-to-EBITDA of 1.3x (leverage ticked up after Alchemy acquisition and return of cash to shareholders). Management expects to reach ~1x organically by end-2026.
Operational Challenges at St. Louis (Residual)
Operational constraints at the St. Louis site were cited as holding back Coatings performance; while debottlenecking improved output (~20% improvement), further work remains to fully unlock capacity (~30% opportunity originally cited).
Pharma Disposal Reduces Revenue Base
Agreement to sell the pharma manufacturing business (prior-year revenue $35M) removes a revenue stream and will change group scale and mix, although management positions the sale as strategically positive and expects to distribute net proceeds to shareholders.
Macro and Geopolitical Uncertainty
Management flagged ongoing macro/geopolitical risk (e.g., recent Middle East developments) and softer Q4 exit rates; seasonality remains (approx. 52/48 H1/H2), and external uncertainty could affect 2026 outcomes.
Company Guidance
The management reiterated medium‑term guidance under the Elevate Elementis plan of mid‑single‑digit revenue growth, operating margins above 23%, 3‑year operating cash conversion >90% and ROCE (ex‑goodwill) >30%, alongside a target to lift innovation sales from 16.4% in 2025 toward 20%; near‑term technicals include 2026 CapEx of 4–5% of revenue, R&D rising from 2% to 3% of revenue (a 50% increase), a goal to reach ~1x net debt/EBITDA organically by end‑2026 (net debt/EBITDA was 1.3x at year‑end with net debt $185.4m), and a ~30% dividend payout policy (2025 full‑year dividend $0.043, final $0.03); 2025 results to keep in mind as context were revenue $597.5m (‑1% reported, ‑1.9% CC), adjusted operating profit $126.7m (+4.6%), adjusted margin 21.2% (+150bps), adjusted EPS $0.137 (+14.2%), free cash flow $41m, and the company expects to distribute net proceeds from the announced pharma disposal (pharma revenue $35m in the prior year); cost‑savings deliverables include $18m of self‑help savings in 2025, completion of elements of a $30m program ( ~$12m via Fit for the Future) plus an additional $10m target (of which $6m is already delivered, $4m to come by end‑2026), while operational targets include a 20% improvement at St. Louis (two‑thirds of a 30% unlock) and achieving half of a 20% On‑Time‑In‑Full uplift.

Elementis Financial Statement Overview

Summary
Balance sheet strength improved materially with sharply lower debt and a solid equity base, and the company remained free-cash-flow positive. However, revenue has been declining recently and net losses persisted in 2024–2025, keeping overall fundamentals in a stabilizing-but-not-strong profile.
Income Statement
46
Neutral
Profitability is inconsistent. Revenue declined in 2025 (-8.1%) after modest growth in 2024, and net losses persisted in 2024–2025 (net margin about -6.5% to -7.6%) after a profitable 2023. A key positive is underlying operating improvement in 2025, with a solid gross margin (~46.6%) and strong operating margin (~17.5%) versus negative operating results in 2024, but the continued net loss suggests below-the-line costs or one-offs are still pressuring bottom-line earnings.
Balance Sheet
74
Positive
Leverage improved materially, with total debt down sharply (from ~254m in 2024 to ~70m in 2025) and debt relative to equity falling to ~0.11, which meaningfully reduces financial risk. Equity remains sizable (~644m) despite some decline, providing a solid capital base. The main weakness is returns to shareholders remain negative recently (return on equity negative in 2024–2025), reflecting the ongoing net losses.
Cash Flow
63
Positive
Cash generation is a relative strength: operating cash flow and free cash flow stayed positive in 2025 (~76.8m and ~54.0m). However, free cash flow fell meaningfully in 2025 (about -20.6% growth), and cash conversion vs earnings is only moderate (operating cash flow covers less than half of EBIT in 2025, down from 2024). Overall, the business is still producing cash, but momentum softened in the most recent year.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue610.04M738.30M713.40M736.40M709.40M
Gross Profit284.34M338.00M284.30M298.90M289.00M
EBITDA107.00M27.20M115.60M23.70M87.30M
Net Income-46.45M-47.80M26.50M-51.10M2.50M
Balance Sheet
Total Assets1.12B1.31B1.51B1.63B1.84B
Cash, Cash Equivalents and Short-Term Investments54.62M59.90M65.80M54.90M84.60M
Total Debt256.69M253.90M300.90M453.70M522.70M
Total Liabilities470.87M551.40M664.10M843.10M935.60M
Stockholders Equity644.13M757.00M847.30M783.90M901.00M
Cash Flow
Free Cash Flow54.01M62.20M38.60M29.90M13.60M
Operating Cash Flow76.78M100.00M76.80M77.00M66.70M
Investing Cash Flow-8.47M-37.50M101.10M-46.90M-65.00M
Financing Cash Flow-84.23M-59.80M-168.00M-57.80M-25.30M

Elementis Technical Analysis

Technical Analysis Sentiment
Negative
Last Price152.40
Price Trends
50DMA
167.14
Negative
100DMA
165.07
Negative
200DMA
163.45
Negative
Market Momentum
MACD
-2.29
Positive
RSI
29.46
Positive
STOCH
12.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ELM, the sentiment is Negative. The current price of 152.4 is below the 20-day moving average (MA) of 166.94, below the 50-day MA of 167.14, and below the 200-day MA of 163.45, indicating a bearish trend. The MACD of -2.29 indicates Positive momentum. The RSI at 29.46 is Positive, neither overbought nor oversold. The STOCH value of 12.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ELM.

Elementis Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
£548.38M22.536.22%9.48%0.58%61.58%
66
Neutral
£3.86B60.706.17%3.45%2.36%-13.99%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
60
Neutral
£3.26B-46.91-5.62%3.54%-4.60%-126.46%
60
Neutral
£124.27M32.058.02%4.08%1.12%-0.70%
58
Neutral
£866.16M-28.063.37%1.34%-11.78%-92.61%
51
Neutral
£29.34M-1.25-7.26%-4.41%2.29%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:ELM
Elementis
152.40
4.22
2.85%
GB:CRDA
Croda International
2,767.00
-270.82
-8.92%
GB:JMAT
Johnson Matthey
1,945.00
558.71
40.30%
GB:SYNT
Synthomer
17.94
-120.66
-87.06%
GB:TET
Treatt plc
210.50
-178.99
-45.95%
GB:VCT
Victrex
630.00
-285.59
-31.19%

Elementis Corporate Events

Regulatory Filings and Compliance
Elementis Reports No Share Issuances Under Employee and Incentive Schemes
Neutral
Mar 5, 2026

Elementis reported that across its various executive share option schemes, savings-related share option schemes and long term incentive plans, there were no new shares issued or allotted in the six months to 28 February 2026. The balances of unallotted securities in each scheme remained unchanged, while the company’s total shares in issue stood at 569,315,667 at the end of the period, indicating stable capital structure and no dilution for existing shareholders over this timeframe.

The most recent analyst rating on (GB:ELM) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresM&A Transactions
Elementis lifts profits and margins as it sharpens focus on specialty chemicals
Positive
Mar 5, 2026

Elementis reported resilient 2025 results in a weak demand environment, with revenue edging down 1% to $597.5m but adjusted operating profit rising 6.3% to $126.7m and margins improving to 21.2%. Personal Care was the standout, with revenue up 3.3% and operating margins jumping to 32.4%, while Coatings sales declined amid soft demand, though margins remained robust at 18.9%.

The group advanced its Elevate Elementis strategy by completing its transformation into a pure-play specialty chemicals business, delivering $18m of cost savings and boosting innovation-driven revenue to 16.4%. It bought natural skincare specialist Alchemy, agreed to sell its pharmaceutical manufacturing unit to ABF with proceeds earmarked for shareholders, completed a £40m buyback, and lifted the full-year dividend 7.5%, underscoring confidence despite ongoing macro and coatings-market headwinds.

The most recent analyst rating on (GB:ELM) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresM&A Transactions
Elementis sharpens specialty chemicals focus as profit margins rise in 2025
Positive
Mar 5, 2026

Elementis reported resilient 2025 results in a soft demand environment, with revenue slipping 1% to $597.5m but adjusted operating profit rising 4.6% at constant currency to $126.7m and margins improving to 21.2%. Personal Care led growth with revenues up 3.3% and a 32.4% margin, offsetting weaker Coatings demand, while net debt stood at $185.4m, leverage remained low at 1.3x EBITDA, and the dividend increased 7.5% alongside a completed £40m share buyback.

Strategically, the group completed the Talc disposal to become a pure-play specialty chemicals business, launched its Elevate Elementis growth plan, and agreed to sell its pharmaceutical manufacturing unit to Associated British Foods to sharpen its focus and enhance margins. Elementis also acquired Alchemy in fast-growing natural skincare, lifted capacity at its St. Louis site, delivered $18m of cost savings, and signalled it expects to return net cash proceeds from the pharma sale to shareholders while remaining cautiously optimistic amid ongoing weakness in coatings demand and geopolitical uncertainty.

The most recent analyst rating on (GB:ELM) stock is a Buy with a £2.10 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Regulatory Filings and Compliance
Elementis Updates Total Voting Share Capital for FCA Disclosure Thresholds
Neutral
Mar 2, 2026

Elementis plc has confirmed that as of 28 February 2026 it has an issued and voting share capital of 569,315,667 ordinary shares of 5 pence each, of which 67,986 are held in treasury. This updated share count provides the official denominator for investors when calculating their holdings and determining whether they must disclose positions under the UK Financial Conduct Authority’s transparency rules, clarifying ownership thresholds for shareholders and the market.

The most recent analyst rating on (GB:ELM) stock is a Buy with a £2.10 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Executive/Board ChangesRegulatory Filings and Compliance
Elementis Announces Retirement of Long‑Serving Non‑Executive Director
Neutral
Feb 25, 2026

Elementis plc has announced a forthcoming change to its board, with independent non-executive director Dorothee Deuring set to retire on 28 February 2026. Her departure will also see her step down from the Audit, Nomination and Remuneration Committees after nine years of service, marking a planned refresh of the company’s governance structure and potentially opening room for new expertise on the board.

Chair John O’Higgins publicly thanked Deuring for her commitment and contribution over nearly a decade, underscoring the value of her role in board oversight. The move, made in line with UK listing requirements on director tenure and governance transparency, signals Elementis’s adherence to established corporate governance norms, which may reassure investors focused on board independence and regulatory compliance.

The most recent analyst rating on (GB:ELM) stock is a Buy with a £2.10 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Regulatory Filings and Compliance
Elementis Updates Total Voting Share Capital for Regulatory Disclosure
Neutral
Feb 2, 2026

Elementis plc reported that as of 31 January 2026 it has an issued and voting share capital of 569,303,958 ordinary shares of 5 pence each, of which 79,695 shares are held in treasury. The updated share count provides the official denominator for investors when calculating and disclosing their ownership stakes under UK transparency regulations, ensuring accurate reporting of significant shareholdings and maintaining compliance with market disclosure standards.

The most recent analyst rating on (GB:ELM) stock is a Buy with a £2.10 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Elementis Beats Profit Expectations as Strategy and Acquisition Lift Margins
Positive
Jan 21, 2026

Elementis reported a resilient 2025 trading performance, with revenue expected to be in line with market consensus and adjusted operating profit marginally ahead, supported by improved operating margins. Management attributed the margin gains to its Elevate Elementis strategy, operational simplification, ongoing cost savings and the bolt‑on acquisition of UK-based Alchemy Ingredients in November 2025, which together are intended to bolster efficiency and future growth. The group continues to generate positive free cash flow, leaving net debt (pre IFRS 16) at about $185m after a £40m share buyback, the sale of its disused Eaglescliffe site and associated environmental liabilities, and the Alchemy purchase, underscoring balance sheet strength and flexibility for future capital allocation. The board also noted that its chair succession process remains underway, with a further update to follow.

The most recent analyst rating on (GB:ELM) stock is a Buy with a £190.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Regulatory Filings and Compliance
Elementis Confirms Total Voting Rights and Share Capital as of Year-End 2025
Neutral
Jan 2, 2026

Elementis plc has reported that, as of 31 December 2025, its issued and voting share capital consists of 569,295,044 ordinary shares of 5 pence each, of which 88,609 are held in treasury. The disclosed figure will serve as the reference denominator for shareholders when calculating their holdings for regulatory disclosure purposes under the UK Financial Conduct Authority’s transparency rules, helping investors determine whether they must notify changes in their interests in the company.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Executive/Board Changes
Elementis Confirms CFO Transition as Kearney-Croft Joins Board
Neutral
Jan 2, 2026

Elementis plc has confirmed a planned change in its senior leadership, with the appointment of Kath Kearney-Croft as Chief Financial Officer effective 1 January 2026 and the simultaneous departure of former CFO Ralph Hewins from both his role and the company’s Board. The transition, first announced in September 2025, signals continuity in the group’s financial stewardship, with the Board highlighting the orderly handover and expressing appreciation for Hewins’ role in ensuring a smooth changeover at the top of the finance function.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Other
Elementis CEO Retains Shares Following Maturity of Savings-Related Options
Positive
Dec 24, 2025

Elementis PLC has disclosed a management share transaction involving its chief executive officer and director Luc Van Ravenstein. Following the maturity of 40,800 US savings-related share options granted in September 2023, Van Ravenstein has retained 37,174 Elementis shares at an option price of 94.86 pence per share, with the transaction executed on 23 December 2025 in London, underscoring continued equity alignment between senior management and shareholders.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Business Operations and StrategyStock Buyback
Elementis Executes Share Buyback to Optimize Capital Structure
Positive
Dec 15, 2025

Elementis, a company engaged in a share buyback program, has repurchased 136,378 of its ordinary shares at an average price of 167.9346 pence per share. This transaction, conducted through Deutsche Bank AG, London Branch, is part of a strategic move to reduce the number of shares in circulation, potentially increasing the value for existing shareholders and adjusting the company’s capital structure.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Stock Buyback
Elementis Completes £40 Million Share Buyback Programme
Positive
Dec 15, 2025

Elementis PLC has successfully completed its share buyback programme, purchasing over 24 million ordinary shares at a total cost of nearly £40 million. This move, which involved cancelling a significant portion of its issued share capital, is likely to impact the company’s financial structure and could influence its market positioning by enhancing shareholder value.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Stock Buyback
Elementis Executes Share Buyback, Reducing Share Count
Neutral
Dec 11, 2025

Elementis, a company involved in a share buyback program, announced the purchase and cancellation of 165,000 of its own ordinary shares at an average price of 165.6504 pence per share. This transaction reduces the total number of ordinary shares in issue to 569,388,598, impacting the company’s voting rights and potentially affecting shareholder interests.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Business Operations and StrategyStock Buyback
Elementis Executes Share Buyback to Optimize Capital Structure
Positive
Dec 10, 2025

Elementis, a company involved in the chemical industry, has executed a share buyback program as announced earlier this year. The company repurchased 165,000 of its ordinary shares at an average price of 165.5403 pence per share, which will be canceled, reducing the total number of shares in circulation. This move is part of Elementis’ strategy to manage its capital structure and potentially enhance shareholder value by reducing the number of shares outstanding, thereby increasing earnings per share.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Stock Buyback
Elementis Executes Share Buyback, Reducing Share Count
Neutral
Dec 9, 2025

Elementis plc, a company involved in a share buyback programme, has repurchased 165,000 of its ordinary shares at an average price of 165.8570 pence per share for cancellation. This transaction reduces the total number of ordinary shares in issue to 569,718,598, which may affect shareholder voting rights and interest calculations.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Business Operations and StrategyStock Buyback
Elementis Executes Share Buyback to Optimize Capital Structure
Neutral
Dec 8, 2025

Elementis, a company involved in a share buyback program, has repurchased 140,000 of its own ordinary shares at an average price of 166.4362 pence per share. This transaction, conducted through Deutsche Bank AG, London Branch, results in a total of 569,883,598 ordinary shares in issue, with the same number of voting rights available to shareholders. The buyback is part of a strategic move to manage the company’s capital structure and potentially enhance shareholder value.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Stock Buyback
Elementis Executes Share Buyback to Optimize Shareholder Value
Neutral
Dec 8, 2025

Elementis plc, a company engaged in a share buyback programme, has announced the repurchase of 14,813 of its own ordinary shares at an average price of 166.1023 pence per share. This transaction is part of a previously announced buyback initiative aimed at reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares. Following this purchase, the total number of shares in issue will be 570,023,598, with 131,433 shares held in treasury, impacting the voting rights and shareholding calculations for stakeholders.

The most recent analyst rating on (GB:ELM) stock is a Hold with a £178.00 price target. To see the full list of analyst forecasts on Elementis stock, see the GB:ELM Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 07, 2026